Episurf Medical (NASDAQ: EPIS B) today announces that the scientific abstract “Erfolgreiche klinische Ergebnisse mit einer patienten-spezifischen Endoprothese zur Behandlung von fokalen, vollschichtigen Knorpelschäden des Kniegelenks” (Eng: Successful clinical results of an individualised endoprosthesis for treatment of focal full-thickness cartilage lesions in the knee) by Dr. med. Johannes Holz et al. will be presented at the German annual congress of EKB2019 (Endoprothetikkongress Berlin). The congress will take place in Berlin, Germany on February 14-16, 2019. The abstract focuses on interim results from a European multicenter study with the Episealer® knee implant. Dr. med. Holz from OrthoCentrum Hamburg, Germany summarises the results saying “The study shows very good clinical outcomes in the treatment of fourth-degree chondral and osteochondral symptomatic damage of the femoral condyles and trochlea with a new patient-specific mini-prosthesis using patient-individualised instruments”.
“We appreciate the interest in the clinical results from follow–up of patients who received Episealer® implants. The results show high patient reported scores and low revision rate. Our customers continue to report positive results and confirm the treatment gap” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlContact:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[HtmlTitle:protected] => <h1 style="font-family: arial,helvetica,sans-serif;">Clinical results for Episealer® to be presented at German clinical congress</h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] => <p style="font-size: 10pt;font-family: arial,helvetica,sans-serif;"><span style="font-size: 10pt;"><strong></strong></span></p>
[Body:protected] => Episurf Medical (NASDAQ: EPIS B) today announces that the scientific abstract “Erfolgreiche klinische Ergebnisse mit einer patienten-spezifischen Endoprothese zur Behandlung von fokalen, vollschichtigen Knorpelschäden des Kniegelenks” (Eng: Successful clinical results of an individualised endoprosthesis for treatment of focal full-thickness cartilage lesions in the knee) by Dr. med. Johannes Holz et al. will be presented at the German annual congress of EKB2019 (Endoprothetikkongress Berlin). The congress will take place in Berlin, Germany on February 14-16, 2019. The abstract focuses on interim results from a European multicenter study with the Episealer® knee implant. Dr. med. Holz from OrthoCentrum Hamburg, Germany summarises the results saying “The study shows very good clinical outcomes in the treatment of fourth-degree chondral and osteochondral symptomatic damage of the femoral condyles and trochlea with a new patient-specific mini-prosthesis using patient-individualised instruments”.
“We appreciate the interest in the clinical results from follow-up of patients who received Episealer® implants. The results show high patient reported scores and low revision rate. Our customers continue to report positive results and confirm the treatment gap” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
[HtmlBody:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Episurf</span><span style="font-size: 10pt;"> Medical (NASDAQ: EPIS B) today announces that the scientific abstract “</span><span style="font-size: 10pt;">Erfolgreiche</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">klinische</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">Ergebnisse</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">mit</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">einer</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">patienten-spezifischen</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">Endoprothese</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">zur</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">Behandlung</span><span style="font-size: 10pt;"> von </span><span style="font-size: 10pt;">fokalen</span><span style="font-size: 10pt;">, </span><span style="font-size: 10pt;">vollschichtigen</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">Knorpelschäden</span><span style="font-size: 10pt;"> des </span><span style="font-size: 10pt;">Kniegelenks</span><span style="font-size: 10pt;">” </span><span style="font-size: 10pt;">(</span><span style="font-size: 10pt;">Eng</span><span style="font-size: 10pt;">: Successful clinical results of an </span><span style="font-size: 10pt;">individualised</span><span style="font-size: 10pt;"> endoprosthesis for treatment of focal full-thickness cartilage lesions in the knee)</span><span style="font-size: 10pt;"> by Dr. med. Johannes Holz et al. will be presented at the </span><span style="font-size: 10pt;">German </span><span style="font-size: 10pt;">annual congress of EKB2019 (</span><span style="font-size: 10pt;">Endoprothetikkongress</span><span style="font-size: 10pt;"> Berlin</span><span style="font-size: 10pt;">). The congress will take place in Berlin, Germany on February 14-16, 2019. The abstract focuses on interim results from a European multicenter study with the Episealer® knee implant. Dr. med. Holz from </span><span style="font-size: 10pt;">OrthoCentrum</span><span style="font-size: 10pt;"> Hamburg, Germany </span><span style="font-size: 10pt;">summarises</span><span style="font-size: 10pt;"> the results </span><span style="font-size: 10pt;">saying</span><span style="font-size: 10pt;"> “The study shows very good clinical outcomes in the treatment of fourth-degree chondral and osteochondral symptomatic damage of the femoral condyle</span><span style="font-size: 10pt;">s</span><span style="font-size: 10pt;"> and trochlea with a new patient-specific mini-prosthesis using patient-</span><span style="font-size: 10pt;">individuali</span><span style="font-size: 10pt;">s</span><span style="font-size: 10pt;">ed</span><span style="font-size: 10pt;"> instruments”.</span><span style="font-size: 10pt;" data-ccp-props="{"> </span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">“We appreciate the interest in the clinical results from follow</span><span style="font-size: 10pt;">-</span><span style="font-size: 10pt;">up of patients who received </span><span style="font-size: 10pt;">Episealer</span><span style="font-size: 10pt;">®</span><span style="font-size: 10pt;"> implants. The results show high patient reported scores and low revision rate. Our customers continue to report positive results and confirm the treatment gap” says </span><span style="font-size: 10pt;">Pål</span><span style="font-size: 10pt;"><span style="font-size: 10pt;"> </span></span><span style="font-size: 10pt;">Ryfors</span><span style="font-size: 10pt;">, CEO </span><span style="font-size: 10pt;">Episurf</span><span style="font-size: 10pt;"> Medical.</span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>For more information, please contact:</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><strong>About Episurf Medical</strong></span></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 9309
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 9307
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] =>
[Contact:protected] =>
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 3203881
[EncryptedId:protected] => 5659BCACC77FF482
[IsRegulatory:protected] =>
[PublishDate:protected] => 2019-02-12T10:15:00Z
[LastChangeDate:protected] => 2019-02-12T10:15:10Z
[Title:protected] => Clinical results for Episealer® to be presented at German clinical congress
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/clinical-results-for-episealer--to-be-presented-at-german-clinical-congress,c2738980
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)